@article{f6fd37ae0a524d8e9ebd4ac0fd3d0b5b,
title = "Oseltamivir economisch gunstig bij risicopati{\"e}nten",
keywords = "amantadine, antivirus agent, oseltamivir, rimantadine, zanamivir, bronchitis, chronic disease, clinical trial, cost effectiveness analysis, drug cost, health care cost, high risk population, human, influenza, Influenza B virus, Netherlands, pneumonia, prophylaxis, quality adjusted life year, quality of life, short survey, survival, vaccination, virus infection",
author = "M.J. Postma",
year = "2005",
month = jun,
day = "17",
language = "Dutch",
volume = "140",
pages = "816--817",
journal = "Pharmaceutisch Weekblad",
issn = "0031-6911",
publisher = "Kon. Ned. Mij. ter Bevordering der Pharmacie (KNMP)",
number = "24",
}